Department of Nutrition and Dietetics, Faculty of Healthy Sciences, Artvin Çoruh University, Artvin, Turkey.
Department of Cardiovascular Surgery, SBU Kanuni Training and Research Hospital, Trabzon, Turkey.
Braz J Cardiovasc Surg. 2022 May 2;37(2):212-218. doi: 10.21470/1678-9741-2020-0525.
INTRODUCTION: Coronary artery disease (CAD) is an ischemic condition that occurs as a result of partial or complete interruption of blood flow by narrowing or complete blockage of the vessels supplying the heart, which are called coronary arteries. Our objective in this study is to investigate the RhoA/Rho-associated kinase (ROCK)-1 signaling pathway and oxidative stress in CAD patients. METHODS: A total of 81 individuals aged between 40-70 years - including 45 patients (15 females and 30 males) who were admitted to the Artvin State Hospital Cardiovascular Surgery Clinic and were diagnosed with CAD and 36 healthy volunteers (15 females and 21 males) - participated in this study. Serum samples were tested for total cholesterol, triglyceride, low-density lipoprotein, high-density lipoprotein, malondialdehyde (MDA), superoxide dismutase (SOD), RhoA, and ROCK-1 values. RESULTS: Serum RhoA, MDA levels, and ROCK-1 activity in the CAD group were found to be statistically significantly higher than in the control group (P<0.001). Concordantly, serum SOD activity was found to be statistically significantly lower in the CAD group than in the control group (P<0.001). CONCLUSION: Inhibition of the activity of RhoA/ROCK-1 pathway would be beneficial in treating cardiovascular diseases since this pathway plays an important role in the development of these diseases.
简介:冠心病(CAD)是一种缺血性疾病,由于供应心脏的血管(称为冠状动脉)狭窄或完全阻塞,导致血流部分或完全中断而发生。我们在这项研究中的目的是研究 CAD 患者中的 RhoA/Rho 相关激酶(ROCK)-1 信号通路和氧化应激。 方法:共有 81 名年龄在 40-70 岁之间的个体参与了这项研究,包括 45 名(15 名女性和 30 名男性)被诊断为 CAD 并被收入 Artvin 州立医院心血管外科诊所的患者和 36 名健康志愿者(15 名女性和 21 名男性)。检测了血清样本中的总胆固醇、甘油三酯、低密度脂蛋白、高密度脂蛋白、丙二醛(MDA)、超氧化物歧化酶(SOD)、RhoA 和 ROCK-1 值。 结果:CAD 组的血清 RhoA、MDA 水平和 ROCK-1 活性均明显高于对照组(P<0.001)。相应地,CAD 组的血清 SOD 活性明显低于对照组(P<0.001)。 结论:抑制 RhoA/ROCK-1 通路的活性将有益于治疗心血管疾病,因为该通路在这些疾病的发展中起着重要作用。
Braz J Cardiovasc Surg. 2022-5-2
BMC Cardiovasc Disord. 2016-10-11
Am J Physiol Gastrointest Liver Physiol. 2014-4-17
Am J Physiol Heart Circ Physiol. 2020-6-19
Eur Rev Med Pharmacol Sci. 2020-5
Diabetes Metab Res Rev. 2025-7
Biomolecules. 2025-6-18
Pharmacol Rep. 2024-10
Pflugers Arch. 2023-7
Cardiovasc Ther. 2019-11-26
Clin Investig Arterioscler. 2019-12
Nutr Metab Cardiovasc Dis. 2019-9-24
Nutrients. 2019-9-4
Prostaglandins Other Lipid Mediat. 2019-7-3